NewBiologix today announced the launch of the Xcell™ Portfolio. The Xcell suite of advanced technologies offers reliable and scalable solutions that address critical challenges in gene therapy production, such as low yields, batch heterogeneity, scalability, and high cost. The Xcell suite also provides deeper insights and comprehensive analysis of rAAV quality—an ongoing challenge in the field. By integrating its proprietary HEK293-based cell lines with advanced production tools and analytical testing services, the Xcell Portfolio streamlines the journey from research to commercialization, accelerating the development of safer and more effective gene therapies for patients.

“The innovative Xcell Portfolio powered by NewBiologix draws on our leadership’s decades of experience in cell line development and our focus on precision, reliability, and scalability,” said Igor Fisch, Ph.D., CEO of NewBiologix. We are committed to catalyzing rAAV development for research institutions, CDMOs, and biotechnology and pharmaceutical companies. Our innovative suite of services and cell line solutions tackles complex challenges in gene therapy production, ensuring that safe and effective treatments are accessible to patients.”

The Xcell Portfolio includes a suite of advanced technologies designed for excellence in gene & cell therapy production:

“With our Xcell Portfolio, we’re looking forward to collaborating with leading gene therapy companies to unlock new therapeutic potential and accelerate production of rAAVs,” said Déborah Ley, Ph.D., Chief Operating Officer, NewBiologix.

For more information, please visit www.newbiologix.com/xcell-portfolio or email contact@newbiologix.com.

‍

Source to the original press release

‍

General
HomepageAbout usNewsCareersContact
Xcell™ PORTFOLIO
OverviewXcell™ Genomic Analytical PlatformXcell™ Eng-HEK293 Cell LineXcell™ rAAV Testing Platform
Technology
OverviewCell therapiesGene therapiesNGS
Legals
Legal noticePrivacy policy
Social media
Linkedin